Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: warren kaplan who wrote (83)	1/27/1998 6:40:00 PM
From: Amigo Mike	Respond to of 586

FDA approval should come very quickly as the PORSORBA column is already FDA approved for another application. Should be very quick. Mike

To: warren kaplan who wrote (83)	1/27/1998 8:09:00 PM
From: Martin Spallone	Read Replies (2) \| Respond to of 586

We need to stay ahead of the curve. Don't rule out a buyout play. I understand that a few other companies will have drugs for RA but are still in Phase III. 100MM is pennies to a Centocor looking to couple their drug with an out-patient procedure for patients that have refratory results with the current and future drugs. The conference call today was very interesting. They are playing it conservative with market predictions. I think at 200MM, CYPB is more fairly valued going forward. It all depends on future test results and private placements, etc., things they do to keep the doors open until approval. There were some real long term positives in the call today if one listened closely. I think the call today was representative of a well managed biotech. This company is not a Comparator Systems, if anyone knows who IDID is/was.